当前位置: 首页 >> 检索结果
101. Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results.
作者: Robert L Coleman.;Gini F Fleming.;Mark F Brady.;Elizabeth M Swisher.;Karina D Steffensen.;Michael Friedlander.;Aikou Okamoto.;Kathleen N Moore.;Charles A Leath.;David Cella.;Zhaowen Sun.;Shilpen Patel.;Zequn Tang.;Christine K Ratajczak.;Carol Aghajanian.;Michael A Bookman.
来源: Eur J Cancer. 2025年225卷115587页
In the VELIA trial, the addition of veliparib to standard first-line platinum-based chemotherapy and continued as maintenance resulted in significantly longer median progression-free survival (PFS) compared with carboplatin plus paclitaxel induction therapy alone (23.5 vs 17.3 months; p < 0.001) in patients with ovarian cancer. We now report final overall survival (OS) and updated safety and disease-related symptoms (DRS) from patient-reported outcomes of the trial.
102. Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study.
作者: Lingfang Xia.;Keqiang Zhang.;Ying Tang.;Guonan Zhang.;Danbo Wang.;Hanmei Lou.;Naifu Liu.;Hongping Zhang.;Hongwei Chen.;Ke Wang.;Shuqing Wei.;Li Wang.;Kun Gao.;Guiling Li.;Huifeng Zhang.;Yuanjing Hu.;Weidong Zhao.;Yunyan Zhang.;Hong Zhu.;An Lin.;Jinwei Miao.;Guohua Yu.;Keqin Hua.;Liangdan Tang.;Ziling Liu.;Bingzhong Zhang.;Hongwei Li.;Min Zheng.;Xiaohong Wang.;Fenghu Li.;Xinfeng Yang.;Huaijun Zhou.;Bairong Xia.;Xianfeng Zhou.;Yuting Wang.;Quanren Wang.;Xiaohua Wu.
来源: J Clin Oncol. 2025年43卷24期2720-2733页
To compare camrelizumab (an anti-PD-1 monoclonal antibody) plus famitinib (a multitarget receptor tyrosine kinase inhibitor) versus camrelizumab and chemotherapy in recurrent or metastatic cervical cancer (R/M CC).
103. Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial.
作者: D Ciardiello.;L Boscolo Bielo.;F Pietrantonio.;G Martini.;T Troiani.;E Martinelli.;S Natangelo.;M F Bosco.;S Pisconti.;C Nisi.;G Tortora.;L Salvatore.;A Sartore-Bianchi.;S Siena.;L Blasi.;M Messina.;E Ongaro.;A Zaniboni.;C Pinto.;L Antonuzzo.;A Avallone.;N Normanno.;G Santabarbara.;M G Zampino.;R Berardi.;A A Cogoni.;S Leo.;C Lotesoriere.;T P Latiano.;E Maiello.;N Fazio.;G Curigliano.;R Bordonaro.;F De Vita.;F Ciardiello.;S Napolitano.
来源: ESMO Open. 2025年10卷7期105491页
Biomarker-guided therapies are needed for patients with refractory metastatic colorectal cancer (mCRC). Liquid biopsy (LBx) circulating tumor DNA (ctDNA) comprehensive genomic profiling (CGP) could contribute to the clinical tailoring of molecular targeted therapies for these patients.
104. Surgery Versus Ablation for Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF-RCT Trial) and a Nonrandomized Prospective Observational Trial (SURF-Cohort Trial).
作者: Yoshikuni Kawaguchi.;Kiyoshi Hasegawa.;Kosuke Kashiwabara.;Yukiyasu Okamura.;Masayuki Kurosaki.;Masatoshi Kudo.;Mitsuo Shimada.;Naoki Yamanaka.;Masafumi Inomata.;Taro Yamashita.;Ryosuke Tateishi.;Shuichiro Shiina.;Mitsuhiro Fujishiro.;Yutaka Matsuyama.;Masao Omata.;Norihiro Kokudo.
来源: J Clin Oncol. 2025年43卷23期2628-2638页
We conducted a randomized controlled trial (SURF-RCT) to evaluate the efficacy of surgery versus radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). Simultaneously, eligible patients who dissented from random assignment were enrolled in a nonrandomized prospective observational trial (SURF-Cohort). We aimed to report the final analyses of overall survival (OS) and updated recurrence-free survival (RFS) in the SURF-RCT and SURF-Cohort trials.
105. Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer.
作者: Li Sun.;Zhimin Gong.;Lei Wang.;Li Kuang.;Qiao Huang.;Bo Pei.;Xianglin Yuan.;Hong Qiu.
来源: Oncologist. 2025年30卷7期
Nab-paclitaxel is a standard second-line treatment for advanced gastric cancer, but the role of PD-1 inhibitors remains uncertain. This multicenter, randomized phase II trial evaluated the efficacy of nab-paclitaxel plus camrelizumab (Cam-NP) versus nab-paclitaxel alone (NP) in patients with advanced gastric adenocarcinoma resistant to prior treatment.
106. Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020.
作者: Didier Debieuvre.;Lionel Falchero.;Olivier Molinier.;Sébastien Couraud.;Alexis Cortot.;Nicolas Meyer.;Bernard Asselain.;Etienne Auvray.;Dorine Templement-Grangerat.;Acya Bizieux.;Jean Tredaniel.;Sophie Schneider.;Jean-Bernard Auliac.;Olivier Bylicki.;Alexia Letierce.;Hugues Morel.
来源: NEJM Evid. 2025年4卷7期EVIDoa2400443页
Lung cancer is the leading cause of cancer-related death worldwide. The aim of the KBP-2020 study was to describe survival among patients diagnosed with lung adenocarcinoma in France in 2000, 2010, and 2020, outside academic medical centers.
107. Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial.
作者: Roberto A Leon-Ferre.;K Dimitroff.;C Yau.;K V Giridhar.;R Mukhtar.;G Hirst.;N Hylton.;J Perlmutter.;A DeMichele.;D Yee.;L van 't Veer.;H Rugo.;W F Symmans.;M P Goetz.;L Esserman.;J C Boughey.
来源: Breast Cancer Res. 2025年27卷1期115页
Operable triple-negative (TNBC) and HER2-positive breast cancer are often treated with neoadjuvant systemic therapy (NAST). NAST response is highly prognostic, with pathologic complete response (pCR) being associated with low risk of recurrence or death. In contrast, residual disease (RD) after NAST is associated with higher risks and is an indication for escalated postoperative therapy. Recent studies suggest that tumor (T) size and nodal (N) status at diagnosis influence clinical outcomes independent of NAST response. We evaluated the impact of initial clinical stage on clinical outcomes according to response to NAST in I-SPY2.
108. Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial.
作者: Yuankai Shi.;Lin Wu.;Yinghua Ji.;Gongyan Chen.;Baolan Li.;Minghong Bi.;Runxiang Yang.;Liyun Miao.;Guojun Zhang.;Hongjun Gao.;Longhua Sun.;Mingjun Zhang.;Shundong Cang.;Meili Sun.;Wenxiu Yao.;Zhijie Pan.;Jiuwei Cui.;Yi Xiao.;Qiming Wang.; .
来源: Lancet Respir Med. 2025年13卷8期677-686页
Limertinib is a new third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This study aimed to prospectively assess the efficacy and safety of limertinib versus gefitinib as a first-line treatment for locally advanced or metastatic non-small-cell lung cancer (NSCLC) with EGFR-sensitising mutation.
109. Study on the safety and effectiveness of CSP and HSP-EMR in small polyps colorectal cancer in the elderly population: Randomized controlled trial.
作者: Hui-Hui Shang.;Xiu-Mei Tian.;Yan Li.;Rong Zhang.;Yu Wang.;Wen-Xian Song.
来源: Medicine (Baltimore). 2025年104卷25期e42863页
This study evaluates the safety and efficacy of cold snare polypectomy (CSP) and hot snare polypectomy endoscopic mucosal resection (HSP-EMR) for small sessile colorectal polyps in the elderly population.
110. Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole.
作者: Judith-Anne W Chapman.;Jane Bayani.;Sandip SenGupta.;John M S Bartlett.;Tammy Piper.;Mary Anne Quintayo.;Shakeel Virk.;Paul E Goss.;James N Ingle.;Matthew J Ellis.;George W Sledge.;G Thomas Budd.;Manuela Rabaglio.;Rafat H Ansari.;Richard Tozer.;David P D'Souza.;Haji Chalchal.;Silvana Spadafora.;Vered Stearns.;Edith A Perez.;Karen A Gelmon.;Timothy J Whelan.;Catherine Elliott.;Lois E Shepherd.;Bingshu E Chen.;Karen J Taylor.
来源: Breast Cancer Res Treat. 2025年213卷1期51-61页
Statistically standardized estrogen receptor (ER) and progesterone receptor (PgR) differentiated prognosis. Here we examined statistically standardized human epidermal growth receptor 2 (HER2).
111. Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): a randomised, multicentre, non-inferiority trial.
作者: Ujjal Mallick.;Kate Newbold.;Matthew Beasley.;Kate Garcez.;Jonathan Wadsley.;Sarah J Johnson.;Tim Stephenson.;Mark Gaze.;Andrew Goodman.;Sarah Jefferies.;Suganya Sivabalasingham.;Nicholas Slevin.;David P Wilkinson.;Elena Macias-Fernandez.;Danielle Power.;Tom Roques.;Lesley Speed.;Christopher Nutting.;George Mochloulis.;Georgina Gerrard.;Charles Candish.;Sally Morgan.;Devashish Tripathi.;Peter Truran.;Claire Arthur.;Andrzej Wieczorek.;Krishnaswamy Madhavan.;Jillian Maclean.;David Boote.;Dae Kim.;Abigail Pascoe.;Gayani Pitiyage.;Sharon Forsyth.;Emily Ambrose.;Elizabeth Chang.;Kate Farnell.;Allan Hackshaw.
来源: Lancet. 2025年406卷10498期52-62页
Patients with differentiated thyroid cancer can often be treated with postoperative radioiodine (also called radioiodine ablation) after total thyroidectomy. The IoN trial was designed to assess whether recurrence-free survival was non-inferior after no ablation compared with ablation in patients with low-risk differentiated thyroid cancer.
112. Efficacy of losartan plus modified FOLFIRINOX versus modified FOLFIRINOX in advanced pancreatic cancers: A randomized clinical trial (AFPAC Study).
作者: Anant Ramaswamy.;Prabhat Bhargava.;Vikram Gota.;Sujay Srinivas.;Noorzia Sultana.;Sarika Mandavkar.;Poonam Jadhav.;Khushboo Gandhi.;Neha Mer.;Nafisa Khan.;Manan Vora.;Himanshu Gujarathi.;Manish Bhandare.;Vikram Chaudhari.;Shailesh V Shrikhande.;Vikas Ostwal.
来源: Cancer. 2025年131卷13期e35945页
The addition of angiotensin receptor blockers like losartan (L) has been shown to improve outcomes in small prospective studies of pancreatic ductal adenocarcinomas (PDAC).
113. Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study.
作者: Jean-Frédéric Blanc.;Mohamed Bouattour.;Ludovic Gauthier.;Emmanuel Deshayes.;Sophie Guillemard.;Yann Touchefeu.;Fabienne Portales.;Christophe Borg.;Lobna Harguem.;Rosine Guimbaud.;Laurent Mineur.;Marc Ychou.;Thibault Mazard.;Eric Assenat.
来源: Oncologist. 2025年30卷6期
New therapeutic options are needed for biliary tract cancer (BTC). Regorafenib, a multikinase inhibitor, shows promise in refractory digestive cancers and may be beneficial with conventional chemotherapy for BTC.
114. Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial.
作者: Mitsue Saito.;Hirotoshi Iihara.;Mototsugu Shimokawa.;Ryoko Udagawa.;Michiko Tsuneizumi.;Manabu Futamura.;Yuko Ishikawa.;Hideaki Ogata.;Hiroko Bando.;Hiroaki Shima.;Keiko Hosoya.;Toru Mukohara.;Kenichiro Tanaka.;Tomoki Ikuta.;Takahiko Kawate.;Kazushige Ishida.;Katsuya Nakai.;Toshitaka Uomori.;Goro Kutomi.;Rie Ozeki.;Naotake Yanagisawa.
来源: Lancet Oncol. 2025年26卷7期960-970页
The addition of 10 mg olanzapine to the standard triplet antiemetic therapy has shown superiority in controlling chemotherapy-induced nausea and vomiting compared with triplet therapy alone for highly emetogenic chemotherapy, albeit with sedative side-effects. We aimed to investigate if administering 5 mg of olanzapine at home after anthracycline plus cyclophosphamide chemotherapy, rather than before chemotherapy, can maintain efficacy in controlling chemotherapy-induced nausea and vomiting while minimising sedative side-effects and associated risks.
115. Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial.
作者: Eric Assenat.;Meher Ben Abdelghani.;Sophie Gourgou.;Hervé Perrier.;Faiza Khemissa Akouz.;Romain Desgrippes.;Marie-Pierre Galais.;Chloé Janiszewski.;Thibault Mazard.;Yves Rinaldi.;Côme Lepage.;Raphael Tetreau.;Pierre Senesse.
来源: J Clin Oncol. 2025年43卷23期2616-2627页
Oxaliplatin-based adjuvant chemotherapy is used for stage III colon cancer, but may induce disabling neurotoxicity. We previously showed that the incidence of oxaliplatin-induced peripheral neurotoxicity (OIPN) is higher for oxaliplatin doses >3.09 mg per kg of lean body mass (LBM). This proof-of-concept, multicenter, randomized trial assessed whether LBM-based oxaliplatin dose adjustment reduces OIPN (ClinicalTrials.gov identifier: NCT03255434).
116. Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial.
作者: A Llombart-Cussac.;J M Pérez-García.;M Bellet.;F Dalenc.;M Gil-Gil.;M Ruiz-Borrego.;J Gavila.;P Schmid.;P Zamora.;D Wheatley.;E Martínez-de Dueñas.;K Amillano.;S Di Cosimo.;A Anton.;P Cottu.;E Shimizu.;M Fernandez.;M Sampayo-Cordero.;J Cortés.; .
来源: ESMO Open. 2025年10卷7期105309页
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) are the mainstay for hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC). While the approved CDK4/6i have demonstrated significant improvements in progression-free survival (PFS), inconsistencies exist for overall survival (OS) benefits. Here, we report updated efficacy results from PARSIFAL, a randomized phase II study, that evaluated first-line palbociclib with either letrozole or fulvestrant in postmenopausal patients with endocrine-sensitive, HR-positive/HER2-negative ABC.
117. Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer.
作者: Ravindra Uppaluri.;Robert I Haddad.;Yungan Tao.;Christophe Le Tourneau.;Nancy Y Lee.;William Westra.;Rebecca Chernock.;Makoto Tahara.;Kevin J Harrington.;Arkadiy L Klochikhin.;Irene Braña.;Gustavo Vasconcelos Alves.;Brett G M Hughes.;Marc Oliva.;Iane Pinto Figueiredo Lima.;Tsutomu Ueda.;Tomasz Rutkowski.;Ursula Schroeder.;Paul-Stefan Mauz.;Thorsten Fuereder.;Simon Laban.;Nobuhiko Oridate.;Aron Popovtzer.;Nicolas Mach.;Yevhen Korobko.;Diogo Alpuim Costa.;Anupama Hooda-Nehra.;Cristina P Rodriguez.;R Bryan Bell.;Cole Manschot.;Kimberly Benjamin.;Burak Gumuscu.;Douglas Adkins.; .
来源: N Engl J Med. 2025年393卷1期37-50页
The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is unclear.
118. Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study.
作者: Adrian Minson.;Emma Verner.;Pratyush Giri.;Jason Butler.;Wojt Janowski.;Chan Y Cheah.;Sumita Ratnasingam.;Shu Min Wong.;Matthew Ku.;Mark Hertzberg.;Kirsten Herbert.;Nada Hamad.;Costas K Yannakou.;Fiona Swain.;Paul Neeson.;Thiago M Steiner.;Javad Saghebi.;Piers Blombery.;Sally M Hunter.;Molly Robertson.;Lei Shong Lau.;Rory Bennett.;Sean Harrop.;Jing Xie.;John F Seymour.;Michael J Dickinson.
来源: J Clin Oncol. 2025年43卷23期2595-2605页
Improved outcomes are needed for patients with high-risk (HR) large B-cell lymphoma (LBCL) who have <50% chance of cure with first-line (1L) R-CHOP chemotherapy. Patients with high burden or rapid progression are often excluded from 1L trials due to screening requirements. We report the investigator-initiated, phase II COALITION trial of the CD20xCD3 bispecific antibody glofitamab combined with R-CHOP or Pola-R-CHP in younger patients with HR features, designed to minimize time between diagnosis and treatment.
119. Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical Trial.
作者: Shan-Shan Guo.;Xiao-Yun Li.;Li-Ting Liu.;Guo-Dong Jia.;Sai-Lan Liu.;Xue-Song Sun.;Dong-Hua Luo.;Jin-Hao Yang.;Si-Yi Xie.;Yi-Fu Li.;Xing Lv.;Yan-Qun Xiang.;Wei-Xiong Xia.;Rui Sun.;Qing Liu.;Ji-Bin Li.;Pan Wang.;Qi Yang.;Lin Wang.;Dong-Xiang Wen.;Jing Jin.;Jie-Yi Lin.;Hao-Yuan Mo.;Ling Guo.;Chong Zhao.;Xiang Guo.;Qiu-Yan Chen.;Lin-Quan Tang.;Hai-Qiang Mai.
来源: JAMA Oncol. 2025年11卷8期864-873页
It remains uncertain which chemotherapy sequence is more effective for locoregionally advanced nasopharyngeal carcinoma.
120. Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors: A Secondary Analysis of the SAMCO-PRODIGE 54 Randomized Clinical Trial.
作者: Julien Taïeb.;Francesco Giulio Sullo.;Aurélie Lecanu.;Camille Bourreau.;Emilie Barbier.;Annalice Gandini.;Jérémie Bez.;Claire Mulot.;Frederic Di Fiore.;Farid Elhajbi.;Christophe Borg.;Olivier Bouché.;Thomas Aparicio.;Aziz Zaanan.;Thierry André.;David Tougeron.;Valerie Taly.;Pierre Laurent-Puig.
来源: JAMA Oncol. 2025年11卷8期874-882页
Immune checkpoint inhibitors (ICIs) have dramatically transformed the therapeutic landscape of deficient mismatch repair/microsatellite unstable-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC); however, ICI use is challenged by primary resistance and timing of discontinuation. Whether circulating tumor DNA (ctDNA) may be predictive of progression-free survival (PFS) and overall survival (OS) in this treatment context remains unknown.
|